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The insertion of precise genetic modifications by genome editing tools such as 
CRISPR-Cas9 is limited by the relatively low efficiency of homology-directed 
repair (HDR) compared with the higher efficiency of the non-homologous end 
joining (NHEJ) pathway. To enhance HDR, enabling the insertion of precise 
genetic modifications, we suppressed the NHEJ key molecules KU70, KU80 or 
DNA Ligase IV by gene silencing, the Ligase IV inhibitor SCR7 or the coexpression 
of adenovirus 4 E1B55K and E4orf6 proteins in a `traffic light´ and other reporter 
systems. Suppression of KU70 and DNA Ligase IV promotes the efficiency of HDR 
4–5-fold. When co-expressed with the Cas9 system, E1B55K and E4orf6 improved 
the efficiency of HDR up to 8-fold and essentially abolished NHEJ activity in both 
human and mouse cell lines. Our findings provide useful tools to improve the 
frequency of precise gene modifications in mammalian cells.  
 
The clustered, regularly interspaced, short palindromic repeats (CRISPRs)-Cas9 
endonuclease represent a versatile tool for genome engineering, enabling the induction 
of site-specific genomic double-strand breaks (DSBs) by single guide RNAs (sgRNAs)1. 
In mammalian cells DSBs are mostly repaired by the non-homologous end joining 
(NHEJ) pathway2,3, frequently leading to the loss of nucleotides from the DSB ends. This 
enables the efficient construction of knockout alleles through the induction of frameshift 
mutations4. By contrast, the alternative pathway of homology-directed repair (HDR) can 
be utilized for the introduction of precise genetic modifications such as codon 
replacements or reporter insertions by recombination with exogenous targeting vectors, 
serving as repair template5. We reasoned that the efficiency of HDR and thus the 
construction of precise genetic modifications could be boosted by the transient inhibition 
of NHEJ key molecules, similar to what has been observed for Drosophila embryos with 
a genetic DNA Ligase IV deficiency6.  
To quantitatively determine the outcome of CRISPR-induced DSB repair, we first 
generated human HEK293 cells with a `traffic light´ reporter7 (TLR) vector integrated into 
the AAVS1 locus8 (Fig. 1a). HEK293 cells were transfected with an AAVS1 targeting 
vector carrying the TLR insert and Cas9 and AAVS1-specific sgRNA expression 
plasmids (Supplementary Fig. 1.1). Upon selection and genotyping of transfected cells 
we obtained heterozygous (AAVS1TLR/+) and homozygous (AAVS1TLR/TLR) targeted 
clones harboring the TLR construct in the AAVS1 locus (Supplementary Fig. 1.2). The 
reporter includes a CAG promoter for expression of a nonfunctional green fluorescent 
(Venus) gene, disrupted by the replacement of codons 117 - 152 with target sequences 
from the mouse Rosa26 and Rab38 locus, followed by coding regions for a self-cleaving 
2A peptide and a red fluorescent (TagRFP) gene in a reading frame shifted by 2 bp 
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(Supplementary Table 1). CRISPR/Cas9-induced DSBs in the target region that are 
repaired via NHEJ and cause deletions, shift the translation to the frame of the 2A-
TagRFP in about 1/3 of the mutagenic NHEJ events which can then be detected in 
reporter cells by the expression of RFP (Fig. 1b). If an intact Venus coding region is 
provided as repair template, cells that repair the DSBs by HDR express Venus. For 
activation of the TLR reporter we designed two sgRNAs against the Rosa26 target 
sequence, of whichsgRosa26-1 showed a higher activity to induce deletions in the 
endogenous locus of mouse NIH3T3 cells (Fig. 1c).  
Next, we transfected AAVS1TLR/+ cells with an expression  vector for Cas9, blue 
fluorescent protein (BFP) and sgRosa26-1, together with a linearized Venus donor 
plasmid. 72h after transfection the cells were analyzed by FACS, gated for BFP+ 
transfected cells, and the frequency of Venus+ and of RFP+ cells was determined. We 
observed 3% of RFP+ and 5% of Venus+ cells indicating NHEJ or HDR repair events 
respectively, as compared to 0.1% RFP+ and 0.6% Venus+ cells in a control lacking 
sgRosa26-1 (Fig. 1d). Of note, RFP+ cells detected by the TLR assay represent only 1/3 
of all mutagenic NHEJ events. Similar results were obtained with AAVS1TLR/TLR cells 
(Supplementary Fig. 1.3). 
 
For suppression of key NHEJ pathway proteins2,9 by short hairpin (sh) RNAs, we 
added a human H1 promoter to the sgRosa26-1/Cas9/BFP expression vector and 
inserted published shRNA sequences to knockdown KU70, KU80 or DNA Ligase IV. We 
first determined the extent of NHEJ suppression by transfection of AAVS1TLR/+ cells with 
individual sgRosa26-1/Cas9/BFP-H1shRNA expression vectors in the absence of a 
repair template. 72h after transfection the samples were analyzed for RFP+ cells in 
comparison to controls including a scrambled shRNA or lacking an shRNA. A 
substantially suppression of NHEJ repair was observed upon the individual or combined 
knockdown of KU70, KU80 or DNA Ligase IV (Fig. 1e and Supplementary Fig. 1.4). 
Similar results were obtained in AAVS1TLR/TLR cell lines by the knockdown of KU70, 
KU80 or DNA Ligase IV (Supplementary Fig. 1.4). The knockdown of Ligase IV reduced 
its protein level in transfected AAVS1TLR (BFP+) cells by 70% (Supplementary Fig. 1.5).  
As additional approaches DNA Ligase IV inhibition we used the small molecule 
inhibitor SCR710 or the Adenovirus 4 (Ad4) E1B55K and E4orf6 proteins that mediate the 
ubiquitination and proteasomal degradation of DNA Ligase IV11,12. For the coexpression 
of Ad4 proteins, sgRosa26-1, Cas9 and BFP from a vector pair we linked the Ad4 
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E1B55K or the Ad4 E4orf6 gene via self-cleaving 2A peptide sequences to BFP (Fig. 1f). 
Mono- or biallelic AAVS1TLR cell lines were transfected with either sgRosa26-
1/Cas9/BFP expression vector in the presence or absence of SCR7 inhibitor or with both 
sgRosa26-1/Cas9/BFP/Ad4 plasmids. The presence of SCR7 reduced the fraction of 
RFP+ cells in the BFP+ population 4-fold whereas the coexpression of Ad4 proteins lead 
to an 8-fold reduction, compared to controls lacking inhibitor or Ad4 proteins (Fig. 1f and 
Supplementary Fig. 1.6). The coexpression of Ad4 proteins reduced the level of DNA 
Ligase IV protein in transfected AAVS1TLR (BFP+) cells by 93% (Supplementary Fig. 1.5). 
Overall, these results show that the NHEJ repair of CRISPR/Cas9 induced DSBs can be 
suppressed by targeting DNA Ligase IV using RNA interference, SCR7 or, most 
efficiently the Ad4 proteins.  
To assess the effect of NHEJ suppression on HDR, AAVS1TLR/+ cells were transfected 
with Venus repair template together with sgRosa26-1/Cas9/BFP vector (+/- SCR7) or 
with sgRosa26-1/Cas9/BFP vectors including either shRNA constructs targeting KU70, 
KU80, or DNA Ligase IV or the Ad4 proteins. After 72h the frequency of RFP+ and 
Venus+ cells within BFP+ cells  was analyzed by FACS (Fig. 2a, 2b, Supplementary Fig. 
2.1). Venus+ (HDR) cells increased from 5% for sgRosa26-1/Cas9/BFP alone, to 8 – 14 
% in the presence of single shRNAs against KU70, KU80 or DNA Ligase IV, to 25% in 
the presence of shRNAs against KU70 and DNA Ligase IV or 1 µM of the inhibitor 
SCR7, and further to 36% upon the coexpression of the Ad4 proteins. Thus, HDR 
efficiency was enhanced up to 5-fold in the presence of KU70 and Ligase IV shRNAs or 
SCR7, and up to 7-fold by the Ad4 protein pair (Fig. 2c and Supplementary Fig. 2.2). 
Titration of SCR7 on AAVS1TLR/+ cells showed an optimal effect  at 1 µM concentration 
(Supplementary Fig. 2.3). In the presence of two shRNAs, SCR7 or Ad4 proteins we 
noticed diminished fluorescence signals within the population of Venus+ cells at 72h after 
transfection (Fig. 2a, Supplementary Fig. 2.1, 2.3c), indicating reduced Venus 
expression in cells undergoing NHEJ blockade, possibly caused by local chromatin 
remodeling through an extended DNA damage response13,14. However, Venus 
expression was normal in clones established from AAVS1TLR/+ cells targeted in the 
presence of Ad4 proteins, indicating that this effect is only transient (Supplementary Fig. 
2.3d). From the sample expressing the Ad4 proteins, Venus+ cells were sorted, and we 
established 24 clones to confirm the integrity of the repaired TLR loci using PCR and 
sequence analysis (Supplementary Table 2). In contrast to the increase of Venus+ cells, 
RFP+ cells decreased from 3% in the controls to 1.7%, 1.4% or 0.6% in the presence of 
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shRNAs, SCR7 or Ad4 proteins, respectively (Fig. 2a, 2b). Whether the residual NHEJ 
activity relies on the KU/Ligase IV independent alternative end-joining mechanism15 
remains to be determined.  
Assessing the influence of the lengths of homology regions of the repair template on 
HDR efficiency we generated donor templates with 3’ homology regions shortened from 
1450 bp as in the original donor template to 350 bp (Fig. 2d and Supplementary Fig. 
2.4). We transfected AAVS1TLR/+ cells with sgRosa26-1/Cas9/BFP expression vector and 
each of the various donor templates, with or without the coexpression of Ad4 proteins. 
FACS analysis revealed a reduced targeting frequency (2%) for the donor with a 350 bp 
3`homology region whereas the other molecules showed HDR efficiencies in the range 
of 5% (Fig. 2e). In the presence of Ad4 proteins the frequency of Venus+ cells increased 
robustly up to 25% for the 350 bp donor and to 30% for the other donor molecules. In 
line with the previous results, the frequency of RFP+ cells was strongly reduced by the 
coexpression of Ad4 proteins (Fig. 2f). Thus, PCR generated fragments with combined 
homology regions of > 1 kb are effective donors for HDR (Fig. 2e, f and Supplementary 
Fig. 2.4). 
Applying our approach to an endogenous genomic locus we inserted a GFP reporter 
gene into the AAVS1 locus of HEK293 cells. The AAVS1-SA-T2A-GFP targeting vector 
includes AAVS1 homology regions flanking a splice acceptor site and a 2A peptide 
sequence linked to GFP, enabling reporter expression by the AAVS1-derived transcript 
(Fig. 2g). HEK293 cells were cotransfected with a sgAAVS1-1/Cas9/mCherry expression 
plasmid and the AAVS1-SA-T2A-GFP targeting vector, with or without coexpression of 
Ad4 proteins. 72h after transfection the mCherry+ transfected population exhibited 8% 
GFP+ cells upon expression of sgAAVS1-1/Cas9 alone whereas the coexpression of 
Ad4 proteins raised their frequency cells to 66% (Fig. 2h). Thus, in line with the TLR 
results, we observed a 8-fold stimulation of gene targeting at the AAVS1 locus by the 
coexpression of Ad4 proteins. FACS sorting and cloning GFP+ cells 48h after 
transfection, we found correct GFP gene integration in 45 of 48 samples (95%), but only 
in 60% of the clones derived from the sample without Ad4 proteins (Supplementary Fig. 
2.5, Supplementary Table 3), the remaining cells presumably representing random 
integrants.  
Coexpression of Ad4 proteins also promoted HDR efficiency in a mouse Burkitt 
lymphoma (BL) cell line containing an activated PI3 kinase α-subunit16 linked to an IRES 
element and a GFP reporter in the Rosa26 locus. We targeted the GFP using a specific 
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sgRNA and a promoterless donor vector replacing GFP by BFP (Fig. 2i).  The fraction of 
BFP+ cells reports on HDR efficiency and GFP negative cells indicate NHEJ-mediated 
deletion events. Mouse BL cells were electroporated with Cas9 and the BFP 
replacement vector alone or with sgGFP/Cas9 expression plasmid with or without the 
coexpression of Ad4 proteins. Electroporation with sgGFP and Cas9 led to a transfection 
efficiency of 40%, as determined by mCherry expression after 24h. About half of the 
transfected cells (22% in total) had lost GFP expression after 72h (Supplementary Fig. 
2.6) and 10% of the GFP- cells were BFP+ (Fig. 2j). The addition of Ad4 proteins reduced 
transfection efficiency to 27%, but again about half of the transfected cells (14% in total) 
lost GFP expression after 72h (Supplementary Fig. 2.6). Notably, 50% of the GFP- cells 
were now BFP+ (Fig. 2j), indicating a 5-fold stimulation of HDR by Ad4 proteins. 
To assess whether a point mutation can be corrected in a tumor cell line we reverted the 
T24P codon replacement in the Foxo1 gene of mouse BL cells, which renders FOXO1 
resistant to AKT dependent phosphorylation. We transfected BL cells with a mutation 
specific sgRNA and a second sgRNA recognizing the first intron, expression vectors for 
Cas9 and fluorescent reporters without or together with Ad4 proteins and a targeting 
vector containing the reverted codon 24 (and harboring a silent nucleotide replacement) 
and a puromycin resistance gene (Supplementary Fig 2.7). At day 2 transfected cells 
were isolated by FACS sorting, subjected to puromycin selection and 53 or 39 single 
cell-derived clones were established from the sample without or with coexpression of 
Ad4 proteins, respectively. Genotyping of these clones by PCR and sequence analysis 
showed that 43 of the 53 clones derived without Ad4 proteins were mutants, 33 of these 
were heterozygous and 10 clones (19%) were homozygous targeted. In the presence of 
Ad4 proteins we found that all 39 clones were targeted, 24 of these were heterozygous 
and 15 clones (38%) homozygous mutants. Thus, despite the expected high targeting 
rate achieved with a selectable donor vector, the coexpression of Ad4 proteins further 
increased the targeting efficiency to 100% and doubled the net yield of homozygous 
targeted clones.   
In summary, we show that for CRISPR/Cas9-induced mutagenesis the suppression of 
the NHEJ key enzyme DNA Ligase IV is an effective way for engineering precisely 
targeted mutations into the genome of mammalian cells. The activity of Ligase IV can be 
blocked by gene silencing, small molecule inhibition or proteolytic degradation, offering 
diverse approaches for the optimal delivery into target cells. For the proteolytic 
degradation of DNA Ligase IV we selected the E1B55K and E4orf6 proteins of 
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Adenovirus 4, shown to exert minimal influence on other cellular substrates such as 
Mre11 or p53, which are co-targeted by many other serotypes17. Nevertheless, we 
cannot exclude that HDR stimulation by the Ad4 proteins is mediated by the combined 
suppression of DNA Ligase IV and other regulatory proteins. It could be of further 
interest to compare the effect on HDR by the E1B55K and E4orf6 proteins of additional 
adenoviral serotypes and species identified from humans18 and other vertebrates19. 
Furthermore, the use of Ad4 proteins may be also beneficial for the construction of 
targeted mouse mutants, as recently shown for zygotes cultured in the presence of 
SCR720. In populations of cells transfected with a sgRNA, Cas9 and Ad4 protein 
expression plasmids we presently reach knock-in frequencies of up to 50 – 66%. By 
delivering Cas9 and of sgRNAs as synthetic RNAs it may be possible, as shown for 
human iPS cells21, to further enhance gene targeting efficiencies. It will be interesting to 
apply CRISPR/Cas9 mutagenesis combined with NHEJ suppression also to early 
embryos of other model organisms and to primary mammalian cells to achieve gene 
corrections. 
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Online Methods 
 
Traffic light reporter construct The traffic light reporter (TLR) expression construct 
was assembled by cloning of PCR fragments encoding a defective venus (codons 117 – 
152 replaced by a 52 bp segment derived from the mouse Rosa26 locus (sgRNA target 
sequence underlined) and a 56 bp segment from the mouse Rab38 gene) linked to the 
2A peptide from Thosea asigna22 and the coding region of TagRFP23 in a 2 bp shifted 
reading frame (+3), cloned in between the CAG promoter and the polyA region of the 
bovine hGH gene. The CAG promoter was deleted from this plasmid to derive the traffic 
light targeting vector (Supplementary Table 1). 
 
Cell culture and reagents Wild type, AAVS1TLR HEK293, and mouse NIH3T3 cells were 
maintained in DMEM (Gibco) supplied with 15% FBS (Gibco), cells were passaged 3 
times per week. The mouse Burkitt lymphoma cell line, generated from a Burkitt-like 
mouse lymphoma16 was maintained in DMEM supplied with 15% FBS, 2mM HEPES 
(Gibco), 2mM Sodium Pyruvate (Gibco), 2mM L-Glutamine (Gibco), and 1x NAA 
(Gibco), beta-mercapthoethanol (Sigma) and passaged 4 times per week. For 
Puromycin selection, mCherry+ cells were sorted, seeded at 103 cells/well and selected 
with 3 μg/ml of Puromycin for 2 weeks. Then colonies were counted and single cell were 
sorted. The SCR7 inhibitor was purchased  (Xcess Biosciences, San Diego, USA), 12h 
after transfection these cells were maintained in complete medium supplied with 1 μM 
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SCR7 inhibitor until analysis. At SCR7 concentrations of 60 μM and 10 μM we observed 
a reduction of transfection efficiency and of cell viability. 
 
Donor vectors and CRISPR/Cas9-T2A-reporter vectors To generate the 
CRISPR/Cas9-T2A reporter vector, we amplified T2A-mCherry and T2A-BFP fragment 
by overlapping PCR and cloned them into FseI/EcoRI sites of plasmid pX330 (Addgene, 
#42230). The mCherry and BFP templates were derived from the plasmids MSCV-IRES-
mCherry and MSCV-IRES-BFP, respectively, a kind gift of Frank Rosenbauer and Martin 
Janz (Charite, Berlin). To generate the AAVS1-SA-2A-Puro-TLR targeting vector, a 
CAG-Venus+1-P2A+3-mtagRFP+3 cassette was cloned into SalI/NotI sites of AAVS1-
SA-2A-Puro targeting vector (Addgene, #22075). In addition, a SA-2A-GFP fragment 
was generated by overlapping PCR and inserted into the XhoI/SalI sites of the AAVS1 
targeting vector, with the GFP template derived from a pRosa26-IRES-GFP plasmid 
(V.T.C., unpublished). For reporter replacement in the mouse cell line, the P110*-IRES-
BFP-pA construct was generated by overlapping PCR and cloned into the pSTblue-1 
sequencing plasmid (Novagen). For PCR donor templates, fragments were amplified 
with Herculase II Fusion DNA Polymerase (Agilent Technology) from pVenus+1-P2A+3-
tagRFP plasmid using the same forward primer and different reverse primers 
(Supplementary Table 4).  
 
Generation of CRISPR/Cas9 vector expressing shRNA or Ad4 proteins To generate 
CRISPR/Cas9-T2A-BFP/mCherry-hH1-shRNA vectors, the human H1 promoter and 
MCS sequence were generated by overlapping PCR and cloned into the NotI site of the 
CRISPR/Cas9-T2A-BFP/mCherry plasmid. To obtain CRISPR/Cas9-T2A-BFP/mCherry-
P2A-Ad E1B55K or E4orf6 plasmids, the coding regions for adenoviral serotype 4 
proteins were synthesized as mammalian codon optimized sequences (Supplementary 
Table 1) by Genscript (Piscataway, NJ, USA). Using these genes and BFP and mcherry 
template plasmids we amplified BFP/mCherry-P2A-Ad4 E1B55K and BFP/mCherry-
P2A-Ad4 E4orf6 fragments and cloned them into the NheI/EcoRI sites of the 
CRISPR/Cas9-T2A-reporter plasmid by Gibson assembly (New England Biolabs, 
E2611S). 
 
Single guide RNA and short hairpin shRNAs sgRNAs were designed based on 
unique sequences with 20 nt and as the last nucleotide before the PAM signal an A or G 
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was selected. The target sequences should hybridize with the sgRNA scaffold only at 
low energy as predicted by the Mfold web server 
(http://mfold.rna.albany.edu/?q=mfold/rna-folding-form). Complementary oligo-
nucleotides were ordered separately, annealed, phosphorylated and cloned into the BbsI 
sites of the CRISPR/Cas9-T2A-reporter plasmid (Supplementary Table 4). For shRNA 
silencing, shRNA-targeted sequences were selected from previous reports24,25,26,27, 
28,29 (Supplementary Table 4). Complementary oligonucleotides were ordered 
separately, annealed, phosphorylated and cloned into the BamHI/AflII sites of the 
CRISPR/Cas9-T2A-reporter-hH1 plasmid. 
 
Transfection and Electroporation Human HEK293 and mouse NHI3T3 cells were 
plated into 24 well or 6 well plates at 1 day before transfection. At the day of transfection, 
these cells were supplied with new complete medium and the DNA mixed with 
FuGENE® HD Reagent (Promega) in Opti-MEM (Invitrogen) according to the 
manufacturer’s introduction. After 15 minutes of incubation at RT, the mixture was 
dropped slowly into the well. For electroporation, mouse BL cells were harvested and 
counted, 1-2x106 cells resuspended with 3 μg plasmid DNA in 100 μl electroporation 
buffer and transferred to a 0.2 cm cuvette (Sigma) and electroporated using a 
Nucleofactor device (Lonza). Then, cells were transferred into pre-warmed complete 
medium. 
 
Cell sorting and flow cytometry For single cell cloning, single cells were sorted into 96 
well plates with 150 μl complete medium supplied with 10 μg/ml Gentamycin (Lonza). 
These plates were briefly centrifuged and incubated at 370C, 5% CO2, the single cell 
clones were evaluated 3 days after sorting to exclude multiple cell contamination. Cells 
were cultured until confluence and duplicated for genotyping PCR. For the bulk sorting, 
the reporter+ cells were sorted into 15 ml Falcon tubes with complete medium, cells were 
centrifuged and further cultured or used for the isolation of genomic DNA. For flow 
cytometry analysis, HEK293 cells were trysinized and resuspended in PBS/1% BSA 
FACS buffer and analysed with a Fortessa machine (Becton Dickinson). Mouse BL cells 
were harvested, centrifuged and resuspended in PBS/1% BSA FACS buffer. 
 
Genomic DNA isolation, PCR and T7EI assay Reporter+ cells were cultured and 
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harvested at different time points. Single cell clones were duplicated in 96 well plates. 
Genomic DNA was extracted using the QuickExtract DNA extraction kit (Epicentre) 
following the manufacturer’s instruction. For T7EI assay, PCR was done using 
Herculase II Fusion DNA Polymerase (Agilent Technology) with PCR gene-specific 
primers (Supplementary Table 4) using the following conditions: 980C for 3 min; 35-37 
cycles (950C for 20s, 600C for 20s, 720C for 20s) and 720C for 3 min. PCR products were 
run on 2% agarose gels, purified, denatured, annealed, and treated with T7EI (New 
England Biolabs). Cleaved DNA fragments were separated on 2% agarose gels and the 
DNA concentration of each band was quantified using the ImageJ software. Percent 
values of indels were calculated as described 30. For genotyping PCR, genomic DNA 
was amplified using DreamTaq DNA Polymerase (Thermo Scientific) with primers listed 
in Supplementary Table 4. 
 
DNA sequencing PCR products were directly sequenced by specific primers or cloned 
into the pSTBlue-1 Blunt vector (Novagen) following the manufacturer’s protocol. 
Plasmid DNAs were isolated using the NucleoSpin Plasmid (Macherey-Nagel). Plasmids 
were sequenced using T7 forward primer (5'-TAATACGACTCACTATAGGG-3’) by the 
Sanger method (LGCgenomics, Berlin,Germany). 
 
Western blot analysis 
Transfected AAVS1TLR Reporter (BFP+) cells were isolated by FACS and 10 x106 cells 
were lysed on ice in RIPA buffer (20 mM Tris-HCl [pH 7.5], 150mM NaCl, mM EDTA, 1% 
NP-40, 0.1% SDS, 0.1% sodium deoxycholate) for 20-30 min in the presence of 
protease inhibitors (Roche). The whole cell lysates were centrifuged for 10 min at 14.000 
rpm. The supernatants were transferred into new tubes and protein concentrations were  
determined using the BCA protein assay (Biorad). The lysates were boiled at 1000C for 5 
min and loaded on SDS-PAGE gels. Blots were probed with anti-DNA ligase IV (H-300, 
Santa Cruz Biotechnology) and anti-beta-actin (AC-74, Sigma) antibodies. Blots were 
developed with secondary goat anti-rabbit IgG HRP (Southern Biotech) or anti-mouse 
IgG HRP (Southern Biotech) and bands visualised using the ECL detection kit (GE 
Healthcare). 
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Figure Legends 
 
Figure 1 Insertion of a traffic light reporter into the AAVS1 locus of HEK293 cells and 
suppression of the NHEJ pathway. (a) Strategy for insertion of the TLR construct into the 
AAVS1 locus using CRISPR/Cas9 in human HEK293 cells. In the targeted sequence, 
the AAVS1-specific sgRNA is indicated in blue and the PAM signal is shown in red. The 
pAAVS1-TLR targeting vector includes homology arms (HA) of 800 bp flanking a splice 
acceptor (SA)-2A-Puromycin element and the traffic light reporter insert comprising a 
CAG promoter, a Venus gene inactivated by the replacement of 36 codons with target 
sequences from the mouse Rosa26/Rab38 loci (black insert). (b) Diagram of the TLR 
system. CRISPR/Cas9-induced DSBs in the target region, repaired via NHEJ resulting 
into deletions that shift translation by 2 bp, lead to RFP expression. An intact Venus 
coding region serves as repair template for HDR, leading to Venus expression. (c) 
Strategy to target the human AAVS1TLR locus. Two different protospacers targeting the 
mouse Rosa26-derived sequence that interrupts the Venus gene are indicated in blue, 
with PAM signals in red. Empty vectors or sgRosa26-1 or sgRosa26-2/Cas9-T2A-
mCherry expressing vectors were transfected into NIH3T3 cells to test cutting efficiency 
in the endogenous Rosa26 locus. 48h after transfection, mCherry+ cells were sorted and 
PCR and T7EI assays performed. The percentage of indels was quantified by the 
ImageJ software. (d) AAVS1TLR cells were cotransfected with linearized Venus repair 
vector and Cas9/BFP expression plasmids with or without (-) sgRosa26-1. 72h after 
transfection, flow cytometric analysis of BFP+ gated cells displayed 5% of Venus+ (HDR 
repair) cells and 3% of RFP+ (NHEJ repair) cells. The graphs represent triplicate data 
from 1 of 3 independent experiments with similar results, shown as mean ± SD. (e) 
Inhibition of the NHEJ pathway using gene silencing. Scheme of the sgRosa26-1/Cas9-
2A-BFP-H1shRNA expression vector. AAVS1TLR cells were transfected with sgRosa26-
1/Cas9-2A-BFP (-) or sgRosa26-1/Cas9-2A-BFP-H1-shScrambled, -shKU70, -shLIG4 or 
-shKU70 or -shLIG4. 3 days later, these cells were analyzed by flow cytometry, gating 
on BFP+ transfected cells, and the percentage of RFP+ cells was determined. The 
graphs represent triplicate data from 1 of 3 independent experiments with similar results, 
shown as mean ± SD. (f) Suppression of NHEJ repair using the Ligase IV inhibitor SCR7 
or the coexpression of Ligase IV degrading Ad4 E1B55K and E4orf6 (Ad4s) proteins. 
AAVS1TLR cells were transfected with sgRosa26-1/Cas9-2A-BFP expression vector (-) or 
transfected and cultured with SCR7 or were transfected with the sgRosa26-1/Cas9-2A-
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BFP-Ad4-E1B55K or -E4orf6 expression vectors. The samples were analyzed 3 days 
later by flow cytometry, gating on the BFP+ transfected cells, and the percentage of 
RFP+ cells was determined. The graphs represent triplicate data from 1 of 6 independent 
experiments with similar results, shown as mean ± SD. Significance was calculated 
using the Student t-test: ** P < 0.01, *** P < 0.001, ns – not significant. 
 
Figure 2 Enhancement of HDR for CRISPR/Cas9-induced precise gene targeting. (a) 
Improvement of HDR efficiency by suppression of NHEJ key molecules. AAVS1TLR cells 
were cotransfected with linearized Venus repair vector and sgRosa26-1/Cas9/BFP 
expression plasmid together with shRNA cassettes, SCR7 inhibitor or the Ad4 
E1B55K/E4orf6 proteins. The frequency of RFP+ and Venus+ cells within the transfected 
BFP+ population was determined by flow cytometry. The data represent one of four 
independent experiments with similar results. (b) The graph summarizes the frequency 
of RFP+ (red bars, significance compared to the (-) sample) and of Venus+ (green bars; 
significance compared to the (-) sample) cells determined as in Fig. 2a. The y axis is 
represented as log10 scale. The bars represent mean values ± SD. (c) Relative increase 
of HDR efficiency (significance compared to the (-) sample) and of NHEJ suppression 
normalized to the control transfected with sgRosa26-1/Cas9 and targeting vector alone 
(-). The dotted line indicates a more than 2-fold increase of HDR. The bars represent 
mean values ± SD. (d) Use of PCR generated donor templates. Scheme of the TLR 
construct and of PCR donor fragments, having a constant 5’ homology region of 400 bp 
whereas the length of the 3’ homology region varies from 350 bp to 1250bp; as control 
the linearized promoterless Venus repair vector was used. (e) AAVS1TLR cells were 
cotransfected with sgRosa26-1/Cas9/BFP expression vector, the same molar amounts 
(800 fmol) of PCR donors or linearized Venus repair vector without or together with Ad4 
E1B55K/E4orf6 proteins. The percentage of Venus+ and RFP+ cells was analyzed by 
flow cytometry 3 days after transfection. (f) The graph summarizes the frequency of 
RFP+ (red bars) and Venus+ (green bars) cells determined as in Fig. 2e. The data 
represent one of two independent experiments with similar results. The bars represent 
mean values ± SD. (g) Strategy for insertion of a GFP reporter gene into the human 
AAVS1 locus using CRISPR/Cas9 in human HEK293 cells. The CRISPR/Cas9-targeted 
site is shown in Fig. 1a, in the AAVS1-GFP targeting vector the GFP gene is flanked by 
AAVS1 homology regions of 800 bp. (h) HEK293 cells were cotransfected with 
linearized AAVS1-GFP targeting vector and with sgAAVS1-1/Cas9/mCherry expression 
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vector or with sgAAVS1-1/Cas9/ mCherry-Ad4-E1B55K and -E4orf6 expression vectors. 
At day 3, the frequency of GFP+ cells within the population of mCherry+ transfected cells 
was analyzed using the flow cytometric data; shown is one of triplicate samples obtained 
from one of two independent experiments. (i) Fluorescent reporter replacement in the 
mouse BL cell line. The cell line harbors an activated PI3 kinase (P110*)-IRES-GFP-pA 
cassette in the Rosa26 locus. In the targeted GFP sequence, the sgGFP target 
sequence is highlighted in blue and the PAM element in red. DSBs repaired via the 
NHEJ pathway lead to the inactivation of GFP. DSBs repaired via HDR with the pBFP 
donor template lead to the replacement of GFP by the BFP reporter gene. (j) Mouse BL 
cells were electroporated with Cas9/mCherry or sgGFP/Cas9/mCherry expression 
vector and the pBFP donor plasmid without or together with coexpression of the Ad4 
E1B55K/E4orf6 proteins. The frequency of GFP-BFP- (white bars) and GFP-BFP+ (blue 
bars) cells was analyzed at day 3. The graph summarizes triplicate results from one of 
three independent experiments with similar results. The bars represent mean values ± 
SD. Significance was calculated using the Student t-test: ** P < 0.01, *** P < 0.001, **** 
P < 0.0001, ns – not significant. 
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Supplementary Fig. 1.1 Strategy for the insertion of the TLR construct into the AAVS1 locus of 
HEK293 cells using CRISPR/Cas9. 
 
             
(a) T7 endonuclease assay to determine the targeting activity of each sgAAVS1. HEK293 cells were 
transfected and sorted for Cherry expression at 48h, genomic DNA was extracted and the target region 
was amplified by PCR. T7EI was added into heteroduplexed PCR products and the reaction products 
were analyzed by gel electrophoresis and quantified using ImageJ, indicating the cleavage of 35% 
(sgAAVS1-1) or 33% (sgAAVS1-2) of the PCR products.  (b) Sequencing of PCR products showed 
micro-deletions in the targeted AAVS1 locus. (c) Scheme of the TLR insertion experiment, HEK293 
cells were cotransfected with AAVS1-TLR donor and Cas9-T2A-mCherry or sgAAVS1-1/Cas9-T2A-
mCherry expression vectors. mCherry+ cells were sorted, selected with puromycin until day 18, the 
colony number was counted and single cells were sorted. (d) The colony number was evaluated for 
each condition and normalized to the input number of cells.  
Supplementary Fig. 1.2 Genotyping PCR for correct integration of the AAVS1-TLR vector into the 
human AAVS1 locus.  
 
 
                  
 
(a) The human AAVS1TLR targeted allele was detected by an external forward primer and a reverse 
primer located in the inserted cassette. Single cell clones were sorted from cells transfected with 
pAAVS1-TLR donor and Cas9-expression vector or sgAAVS1-1/Cas9 expression vector. (b) 
Genotyping PCR to detect heterozygous/homozygous clones, the wild type band has a size of ~500 bp 
and the targeted band is sized ~300 bp. 
Supplementary Fig. 1.3 Functional test for the TLR system. 
 
 
 
 
(a) Mono- and biallelic AAVS1TLR cells were cotransfected with Venus donor and with Cas9-T2A-BFP 
expressino vector or with sgRosa26-1/Cas9-T2A-BFP expression vector. The frequency of RFP+ 
mutNHEJ and Venus+ HDR cells was analyzed by flow cytometry. (b) Gated on BFP+ transfected 
biallelic cells, the fraction of cells undergoing HDR (green column) or NHEJ (red column) or both (blue 
column) events was further analyzed.  
  
 
 
 
 
 
 
 
 
Supplementary Fig. 1.4 Suppression of the NHEJ pathway using shRNA silencing.  
 
 
       
 
 
(a) For each gene, two shRNAs were selected from published reports and tested for inhibition of NHEJ 
in biallelic AAVS1TLR/TLR cells (Supplementary Table 4). (b) Relates to Fig. 1f, mono-allelic AAVS1TLR/+ 
cells were transfected with CRISPR/Cas9 vector expression shRNA to target KU80 or combinations of 
KU70, KU80 and Ligase IV. The graph represents triplicate data from 1 of 3 similar experiments. (c) 
Biallelic AAVS1TLR cells were transfected with CRISPR/Cas9 vector expressing shRNA to target KU80 
or combinations of KU70, KU80 and DNA Ligase IV. The graphs represent triplicate data from 1 of 3 
similar experiments. 
 
 
Supplementary Fig. 1.5 Suppression of DNA Ligase IV protein by using shRNA or Ad4 proteins.  
 
 
 
  
    
Bi-allelic AAVS1TLR/TLR cells were transfected with sgRosa26-1/Cas9-T2A-BFP, sgRosa26-
1/Cas9/shLIG4-T2A-mCherry or co-transfected with sgRosa26-1/Cas9/Ad4 E4orf6-T2A-BFP 
and Cas9/Ad4 E1B55K-T2A-mCherry expression vectors. (a) The transfection efficiency was analysed 
by flow cytometry at 48h, the reporter+ cells sorted. (b) Sorted cells were lysed and Western blotting 
performed for the detection of DNA Ligase IV (103 kDa) and beta-actin (42 kDa). The data represent 
one of two independent experiments. 
Supplementary Fig. 1.6. Inhibition of the NHEJ pathway using the SCR7 inhibitor or  overexpression 
of Ad4 proteins in biallelic AAVS1TLR cells. 
 
 
 
Biallelic AAVS1TLR/TLR cells were transfected with Cas9-T2A-BFP or sgRosa26/Cas9-T2A-BFP 
expression vectors and treated with SCR7 inhibitor, or were transfected with sgRosa26/Cas9-T2A-BFP-
Ad4 E1B55K/ -E4orf6 expression vectors in the absence of SCR7. BFP+ transfected cells were 
analyzed at day 3. The frequency of RFP+ mutNHEJ cells is indicated. The data represents 1 of 6 
similar experiments. 
 
 
 
 
 
Supplementary Fig. 2.1 Optimization of HDR efficiency using shRNA silencing. 
 
 
 
 
Mono-allelic AAVS1TLR/+ cells were transfected with sgRosa26-1, Cas9 and shRNA against KU80 or 
combinations of KU70 and KU80, or KU80 and DNA Ligase IV. The frequency of Venus+ HDR and 
RFP+ mutNHEJ cells, expressed as the percentage of the transfected BFP+ cells, was determined at 
day 3. 
Supplementary Fig. 2.2. Suppression of the NHEJ pathway to enhance HDR efficiency for 
CRISPR/Cas9-mediated gene targeting in biallelic AAVS1TLR/TLR cells.  
 
 
 
 
 
 
 
(a) Biallelic AAVS1TLR/TLR cells were transfected with Cas9 only or with sgRosa26-1 and Cas9 in the 
presence of shRNAs for gene silencing or SCR7 inhibitor or the coexpression of Ad4 E1B55K/E4orf6 
proteins. The percentage of Venus+ HDR (green bars),  RFP+ mutNHEJ (red bars) and of cells 
undergoing both events (blue bars) was determined at day 3 by flow cytometry. (b) The graph 
summarizes triplicate data from 1 of 3 similar experiments. (c) The normalization of the frequency of 
Venus+ HDR cells to that in cells transfected with sgRosa26-1 and Cas9. The dotted line shows cut of 
interested fold change.  
 
Supplementary Fig. 2.3. Titration of SCR7 and fluorescence analysis of targeted clones. 
 
 
 
(a) AAVS1TLR/+ reporter cells were cultured in serial dilutions of SCR7 and analysed at 48h by FACS for 
the forward (FCS) and side scatter (SSC) parameters. Gating on the population of live cells showed 
that increasing concentrations of SCR7 lead to a gradual decrease of viability. (b) Transfection of 
AAVS1TLR/+ cells with sgRosa26-1/Cas9-T2A-BFP plasmid and linearized Venus donor vector. The 
frequency of transfected BFP+ cells is reduced in the presence of increasing concentrations of SCR7. 
(c) Gating on transfected BFP+ cells, the frequency of Venus+ HDR and RFP+ mutNHEJ cells was 
determined at day 3. (d) FACS re-analysis of two representative targeted AAVS1TLR/+ clones, generated 
through the coexpression of Ad4 proteins (blue curve) or without Ad4 proteins (red curve) for the 
expression of Venus signal, showing a similar mean fluorescence intensity, indicating that the reduced 
reporter expression occurs only transiently.  
 
 
 
Supplementary Fig. 2.4. Optimization of PCR donor templates for CRISPR/Cas9-mediated HDR in 
biallelic AAVS1TLR/TLR cells.  
 
 
(a) Scheme of the forward and reverse primers located in the TLR and the length of PCR donor 
fragments, the purity of PCR products was shown by agarose gel.(b) Biallelic AAVS1TLR/TLR cells were 
cotransfected with sgRosa26-1/Cas9-T2A-BFP expression vector or coexpression of Ad4 
E1B55K/E4orf6 proteins and the same molar concentration of the PCR or linearized Venus plasmid 
donor. The percentage of Venus+ HDR and RFP+ mutNHEJ cells were analyzed by flow cytometry at 3 
days after transfection. The graph summarizes the frequency of RFP+ mutNHEJ (red), Venus+ HDR 
(green), and RFP+ Venus+ mutNHEJ-HDR (blue) cells. The data represent results from 1 of 2 similar 
experiments. The bars show mean values ± SD. 
Supplementary Fig. 2.5. Detection of correct integration of a GFP cassette into the human AAVS1 
locus. 
 
 
 
Scheme of the targeted AAVS1 allele and primer locations, single cell clones were sorted from HEK293 
cells transfected with pAAVS1-GFP donor plasmid and sgAAVS1-1/Cas9-T2A-mCherry or sgAAVS1-
1/Cas9-T2A-mCherry-Ad4 E1B55K/E4orf6 expression vectors. PCR was performed using external P1 
forward (outside of 5’ homology arm) and transgene R1 reverse (seeded in T2A sequence) primers, the 
PCR products analyzed on agarose gels and the number of correctly integrated clones was calculated. 
For the genomic DNA loading control, PCR was performed using the P3 forward and R3 reverse 
primers located outside of the 3’ homology arm.    
 
 
 
Supplementary Fig. 2.6. CRISPR/Cas9-mediated HDR in mouse Burkitt lymphoma-like cells.  
 
 
 
 
Scheme of CRISPR/Cas9 delivery, mouse BL cells were electroporated to deliver sgGFP/Cas9-T2A-
mCherry expression vector or coexpession of Ad4 E1B55K/E4orf6 proteins together with the pBFP 
donor plasmid. The cells were analysed at 24h or 72h by flow cytometry. 
 
 
Supplementary Fig. 2.7. Reversion of a Foxo1 point mutation in mouse Burkitt lymphoma-like cells. 
 
 
 
(a) Schematic of the mouse Foxo1 locus, the heterozygous A to C mutation (T24P replacement) in 
exon 1 generates a PAM (red) sequence which is not present in the wild type allele of Burkitt 
lymphoma-like (BL) cell line isolated from a tumor bearing mouse. In the targeted sequence, sgRNAs 
with Foxo1-specific target sequences are indicated in blue and the PAM signal is shown in red. The two 
sgRNAs are located at a distance of 1.2 kb. (b) BL cells were electroporated to deliver sgExon1/Cas9-
T2A-mCherry or sgIntron1/Cas9-T2A-BFP plasmid DNA or both expression vectors, as indicated. 
Reporter positive cells were sorted at 48h, genomic DNA was isolated and a T7EI assay was 
performed, confirming the activity of both sgRNAs.  (c) A segment of the Foxo1 locus was PCR 
amplified using forward and reverse primers as indicated in (a), PCR products derived from undeleted 
alleles have a size of 1.8 kb whereas the 1.2 kb deletion between the sgRNA target sites leads to a 
PCR product of 0.6 kb, indicated by a red arrow. PCR products representing the deleted allele were 
isolated and subcloned into the pSTblue-1 vector for sequencing. Sequence analysis confirmed that the 
expected 1.2 kb gene segment was deleted in mutant Foxo1 alleles. (d) Schematic of codon 
replacement in the mutant Foxo1 allele of BL cells, the mutant C is highlighted in red, the reverting 
(wildtype) A is shown in green and an additional silent mutation (T > C) is shown in blue. The pFoxo1 
donor vector contains in addition a PGK-Puromycin cassette placed into intron 1. (e) Schematic of the 
codon replacement experiment. Mouse BL cells were co-electroporated with pFoxo1 donor and 
sgExon1/Cas9-T2A-mCherry or sgIntron1/Cas9-T2A-BFP plasmids or with both expression vectors in 
the presence or absence of the Ad4 proteins. Reporter positive cells were sorted on day 2 and selected 
with Puromycin for 8 days. At day 10 single cells were sorted, expanded into clones and genomic DNA 
was isolated. The mouse Foxo1 targeted allele was detected by PCR amplification of a 3.2 kb fragment 
using an external reverse primer and a forward primer located in the Puromycin cassette (P1-R1 set). 
The genotyping PCR to distinguish heterozygous and homozygous targeted clones was performed with 
the P2-R2 primer pair, detecting the wildtype allele by a 700 bp band and targeted loci by a 2 kb band. 
(f) Summary of the frequency of Foxo1 targeted clones and of heterozygous and homozygous targeting 
events using the indicated transfection conditions. (g) Sequencing of PCR products derived from 
targeted clones confirmed that the mutant Foxo1 allele was successfully repaired.  
 
 
 
Supplementary Table 1 Gene and protein sequences used this study. 
 
 
 
 
 
 
 
Gene name Sequence (5’ to 3’) 
The TLR DNA 
sequence 
 
Venus – green 
Rosa26 sequence 
– pink,  
Rab38 sequence – 
brown, 
 venus - green 
(tag: stop),  
MluI site - black 
Underlined(tg: 2 
bp frameshift) 
T2A – black 
TagRFP – red 
(tga: stop) 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGG
CCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGCTGATCTGCA
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGCTTCGCCCGC
TACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCAT
CTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGCTGCAACTCCAGTCTTTCTAGA
AGATGGGCGGGAGTCTTCTGGGCAGGCTTATATCAAGCGCTATGTGCACCAAAACTTCTCCTCGCACTACCGGG
CCACCATTGGTGATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACATCGA
GGACGGCGGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCG
ACAACCACTACCTGAGCTACCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTG
GAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGtagACGCGTtgGCCACGAACTTC
TCTCTGTTAAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGGCCTATGGTGTCTAAGGGCGAAGAGCTGATTAA
GGAGAACATGCACATGAAGCTGTACATGGAGGGCACCGTGAACAACCACCACTTCAAGTGCACATCCGAGGGCG
AAGGCAAGCCCTACGAGGGCACCCAGACCATGAGAATCAAGGTGGTCGAGGGCGGCCCTCTCCCCTTCGCCTTC
GACATCCTGGCTACCAGCTTCATGTACGGCAGCAGAACCTTCATCAACCACACCCAGGGCATCCCCGACTTCTT
TAAGCAGTCCTTCCCTGAGGGCTTCACATGGGAGAGAGTCACCACATACGAAGACGGGGGCGTGCTGACCGCTA
CCCAGGACACCAGCCTCCAGGACGGCTGCCTCATCTACAACGTCAAGATCAGAGGGGTGAACTTCCCATCCAAC
GGCCCTGTGATGCAGAAGAAAACACTCGGCTGGGAGGCCAACACCGAGATGCTGTACCCCGCTGACGGCGGCCT
GGAAGGCAGAAGCGACATGGCCCTGAAGCTCGTGGGCGGGGGCCACCTGATCTGCAACTTCAAGACCACATACA
GATCCAAGAAACCCGCTAAGAACCTCAAGATGCCCGGCGTCTACTATGTGGACCACAGACTGGAAAGAATCAAG
GAGGCCGACAAAGAGACCTACGTCGAGCAGCACGAGGTGGCTGTGGCCAGATACTGCGACCTCCCTAGCAAACT
GGGGCACAAACTTAATtga 
Adenovirus 4 
(NCBI accession 
No. NC_003266) 
E4ORF6 protein 
 
MSGNSSIMTRSRTRLALSRHHPYQPPATLPRCEETESRASLVEDHPVLPDCDTLSMHNVSSVRGLP
CSAGFTVLQEFPVPWDMVLTPEELRVLKTCMSVCLCCANIDLFSSQLIHGRERWVIHCHCQNPGSL
RCMAGGTVLAIWFRRIIQGCMFNQRVMWYREVVNLHMPKEIMYMGSVFWRGRHLIYIRIWYDGHV
GSIVPQMSFGWSTLNYGLLNNLVVLCCTYCSDLSEIRIRCCARRTRRLMLRAIGIMRRESLDPDPLS
SSLTERRRQRLLRGLMRHNRPIPFADYDSHRSYSR* 
 
Adenovirus 4 
E1B55K protein 
 
MESRNPFQQGLPAGFLSSSFVENMEVPAPECNLRLLAGTAARHSEDPESPAAGGSRRE
SESRPGPSGGGVADLFPELHRVLTRSSSGRERGIKRERHDETNHRIELTVGLMSRKRPE
TVWWYEVQSTGTDEVSVMHERFSLEQVKTCWLEPEDDWEVAIRNYAKLALRPDRKYKI
TKLINIRNACYISGNGAEVEICLQDRVAFRCCMMNMYPGVVDMDGVTFMNMRFRGDGY
NGTVFMANTKLTVHGCSFFGFNNTCIEAWGQVGVKGCSFSANWMGVVGRTKSMLSVK
KCLFERCHLGVMSEGEARIRHCASTETGCFVLCKGNAKIKHNMICGASDERGYQMLTCA
GGNSHMLAAVHVASHSRKPWPEFEHNVMTRCNMHLGARRGMFMPYQCNLNYVKVLLE
PDVMSRVSLTGVFDMNVEVWKILRYDEYKTRCRACECGGKHARFQPVCVDVTEDLRPD
HLVLSCTGTEFGSSGEESD* 
 
Supplementary Table 2 Sequencing of the traffic light reporter in 10 individual clones after HDR-
mediated repair of the Venus gene. 
 
 
                       The AAVS1TLR locus      CATGTTCATGCCTTCTTCTTTTTCCTACAGATCCTTAATTAAGCCGCCACCATGGTGAGCAAGGGCGAGGAGCTGT 
                                  pVenus donor                                        TAAGCCGCCACCATGGTGAGCAAGGGCGAGGAGCTGT 
 
                                            01 CATGTTCATGCCTTCTTCTTTTTCCTACAGATCCTTAATTAAGCCGCCACCATGGTGAGCAAGGGCGAGGAGCTGT 
                                            02 CATGTTCATGCCTTCTTCTTTTTCCTACAGATCCTTAATTAAGCCGCCACCATGGTGAGCAAGGGCGAGGAGCTGT 
                                            03 CATGTTCATGCCTTCTTCTTTTTCCTACAGATCCTTAATTAAGCCGCCACCATGGTGAGCAAGGGCGAGGAGCTGT 
                                            04 CATGTTCATGCCTTCTTCTTTTTCCTACAGATCCTTAATTAAGCCGCCACCATGGTGAGCAAGGGCGAGGAGCTGT 
                                            05 CATGTTCATGCCTTCTTCTTTTTCCTACAGATCCTTAATTAAGCCGCCACCATGGTGAGCAAGGGCGAGGAGCTGT 
                                            06 CATGTTCATGCCTTCTTCTTTTTCCTACAGATCCTTAATTAAGCCGCCACCATGGTGAGCAAGGGCGAGGAGCTGT 
                                            07 CATGTTCATGCCTTCTTCTTTTTCCTACAGATCCTTAATTAAGCCGCCACCATGGTGAGCAAGGGCGAGGAGCTGT 
                                            08 CATGTTCATGCCTTCTTCTTTTTCCTACAGATCCTTAATTAAGCCGCCACCATGGTGAGCAAGGGCGAGGAGCTGT 
                                            09 CATGTTCATGCCTTCTTCTTTTTCCTACAGATCCTTAATTAAGCCGCCACCATGGTGAGCAAGGGCGAGGAGCTGT 
                                            10 CATGTTCATGCCTTCTTCTTTTTCCTACAGATCCTTAATTAAGCCGCCACCATGGTGAGCAAGGGCGAGGAGCTGT 
                              
           
TCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGCTGATCTGCA 
TCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGCTGATCTGCA 
 
TCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGCTGATCTGCA 
TCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGCTGATCTGCA 
TCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGCTGATCTGCA 
TCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGCTGATCTGCA 
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG 
TCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGCTGATCTGCA 
TCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGCTGATCTGCA 
TCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGCTGATCTGCA 
TCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGCTGATCTGCA 
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG 
 
 
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG 
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG 
 
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG 
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG 
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG 
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG 
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG 
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG 
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG 
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG 
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG 
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGGCCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCG 
                                                                                                                      Rosa26 sequence (sgRosa26-1, PAM) 
AAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGCTGCAACTCCAGTCTTTCTAGAAGATGGGCGGGAGTCTTCTGGGCA 
AAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCA 
 
AAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCA 
AAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCA 
AAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCA 
AAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCA 
AAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCA 
AAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCA 
AAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCA 
AAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCA 
AAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCA 
AAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCA 
                                         Rab38 sequence 
GGCTTATATCAAGCGCTATGTGCACCAAAACTTCTCCTCGCACTACCGGGCCACCATTGGTGATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACATCG 
AGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACATCG 
 
AGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACATCG 
AGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACATCG 
AGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACATCG 
AGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACATCG 
AGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACATCG 
AGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACATCG 
AGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACATCG 
AGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACATCG 
AGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACATCG 
AGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACATCG 
 Supplementary Table 3 Sequencing data confirms the SA-T2A-GFP insertion into the human AAVS1 
locus. 
 
Sequences in the junctions of the 5’ homology arm (Targeting without adenoviral proteins) 
 
                                    outside of homology arm                                  inside of homology arm 
        ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
 
     01 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCAGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     02 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     03 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     04 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     05 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     06 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     07 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     08 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     10 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     11 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...] 
     12 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
 
                                     inside of homology arm                                                SA-T2A sequence 
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA     
 
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA     
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA  
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACGGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA    
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA  
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA 
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA    
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA    
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA    
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA  
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA     
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA    
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA    
 
 
 
Sequences in the junctions of the 5’ homology arm (Targeting with adenoviral proteins) 
 
                                    outside of homology arm                                  inside of homology arm 
        ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
 
     01 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCAGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     02 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     03 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     04 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     05 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     06 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     07 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     08 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     10 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     11 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...] 
     12 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
     13 ACTGGCTTCTGCGCCGCCTCTGGCCCACTGTTTCCCCTTCCCAGGCAGGTCCTGCTTTCTCTGACCTGCATTCTCTCCCCTGGGCCTGTGCCGCTTTCTG[...]     
   
                                     inside of homology arm                                                SA-T2A sequence 
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA     
 
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA     
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA  
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACGGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA    
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA  
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA 
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA    
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA    
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA    
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA  
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA     
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA    
        [...]GGCTCTGGTTCTGGGTACTTTTATCTGTCCCCTCCACCCCACAGTGGGGCAAGCTTCTGACCTCTTCTCTTCCTCCCACAGGGCCTCGAGAGATCTGGCA    
 
Supplementary Table 4 Oligonucleotides used in this study 
 
 
Oligonucleotides used for cloning of sgRNA expression vectors 
Gene target Direction Sequence (5’ to 3’) 
 
Human AAVS1-1 
F CACCGACCCCACAGTGGGGCCACTA 
R AAACTAGTGGCCCCACTGTGGGGTC 
 
Human AAVS1-2 
F CACCGTCACCAATCCTGTCCCTAG 
R AAACCTAGGGACAGGATTGGTGAC 
 
Mouse Rosa26-1 
F CACCGACTCCAGTCTTTCTAGAAGA 
R AAACTCTTCTAGAAAGACTGGAGTC 
 
Mouse Rosa26-2 
F CACCGCGCCCATCTTCTAGAAAGAC 
R AAACGTCTTTCTAGAAGATGGGCGC 
 
GFP reporter gene 
F CACCGCTCGTGACCACCCTGACCTA 
R AAACTAGGTCAGGGTGGTCACGAGC 
 
 
Oligonucleotides used for cloning of shRNA expression vectors 
The shRNAs to target NHEJ molecules were selected from previous reports (see 
references) and cloned into the BamHI/AflII sites of the CRISPR/Cas9-T2A-BFP-
hH1 vector. 
Gene target Target sequence (5’ to 3’) 
KU70-1 GGAAGAGATAGTTTGATTT 
KU70-2 GATGCCCTTTACTGAAAAA 
KU80-1 GAGAACAAGGATGAGATTGCT 
KU80-2 CAAGCAAAGAAGGTGATAA 
LIG4-1 AAGCCAGACAAAAGAGGTGAA 
LIG4-2 GCTAGATGGTGAACGTATG 
Scrambled GGTCTGTACGAACCGATAGGT 
 
 
  
 
 
 
 
 
 
 
Oligonucleotides used for T7EI, PCR genotyping and PCR donor generation 
Gene target Direction Sequence (5’ to 3’) Assays 
 
Mouse Rosa26 
F CGTGCAAGTTGAGTCCATCCGCC T7EI 
R ACTCCGAGGCGGATCACAAGCA 
 
Human AAVS1 
F TCCAGGGGTCCGAGAGCTCAGCTAG T7EI 
R CCAGACAGCCGCGTCAGAGCAGCTC 
AAVS1-TLR 
AAVS1-GFP 
F GGCAGCCTGTGCTGACCCATCGAGTC  
Genotyping R CGGGATTCTCCTCCACGTCACCGCA 
 
AAVS1 
AAVS1-TLR 
F TCCAGGGGTCCGAGAGCTCAGCTAG  
Genotyping R1 
R2 
CGGGATTCTCCTCCACGTCACCGCA 
CCAGACAGCCGCGTCAGAGCAGCTC 
 
AAVS1 loading 
F CCAGGCCACCTACTTGGCCTGGAACC  
Genotyping R CCACAGTTGGAGGAGAATCACC 
 
 
Venus 
F AAGCTTGATTAAGCCGCCACCATGG  
 
Donor  
R350 GTTCGTGGCCAACGCGTCTACTTGT 
R650 CTCTCTCCCATGTGAAGCCCTCAGG 
R950 ATAGTAGACGCCGGGCATCTTGAGG 
R1250 GACACCTACTCAGACAATGCGATGC 
 
 
 
 
 
